性与生殖医学市场：按药物类型和分销管道分類的全球预测 - 2025-2030

2023年性与生殖药物市场价值为316.4亿美元，预计2024年将达到358.3亿美元，复合年增长率为13.34%，到2030年将达到760.3亿美元，预计将达到1000万美元。

生殖医学市场包括多种旨在解决生殖健康问题和性健康的药物。此系列包括避孕药、荷尔蒙疗法、更年期管理药物、勃起功能障碍治疗、性行为感染传染病治疗等。这些药物的需求源于全球对有效生殖健康解决方案的持续需求，这是由于人口增长、性健康意识增强以及对性健康产品的接受程度提高等因素所造成的。治疗应用范围包括避孕、不孕症治疗、性别肯定治疗和荷尔蒙异常管理，最终用途包括个人、医疗保健提供者和性健康诊所。关键的成长要素包括生物技术的进步、医疗保健机会的增加以及社会文化的转变，接受性健康作为整体福祉的重要组成部分。透过远端医疗解决方案扩大可及性和开发个人化医疗方法存在机会，重点是解决普通人群未满足的需求。然而，挑战仍然存在，包括监管障碍、围绕某些药物的社会耻辱以及阻碍吸收的潜在副作用。值得探索的创新领域包括非荷尔蒙避孕药、长效可逆避孕药（LARC）以及针对特定荷尔蒙途径且副作用较少的药物。此外，对奈米技术等新的输送机制的研究以及对植物来源或天然衍生配方的探索可能会提供竞争优势。市场的本质是高度动态和竞争的，需要持续投资于研发，以跟上不断变化的消费者需求和偏好。寻求发展的公司应专注于策略伙伴关係、社区参与以减少耻辱，以及倡导更公平的法规结构以扩大市场准入。对教育和整体健康方法的重视也将在市场扩张中发挥关键作用。

市场动态：揭示快速发展的性与生殖医学市场的关键市场洞察

供需的动态交互作用正在改变性与生殖医学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

• 市场驱动因素
  • 越来越多的老年妇女寻求药物
  • 避孕药具的需求，以防止意外怀孕
  • 智慧型手机和笔记型电脑的网路普及率和可用性较高
• 市场限制因素
  • 治疗和诊断费用上涨
• 市场机会
  • 加大药物研发（R&D）力度
  • 提高妇女对避孕器使用的认识
  • 政府对妇女健康的关注与努力
• 市场问题
  • 与临床服务相关的巨大财务成本

波特五力：驾驭生殖医学市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对性与生殖医学市场的外部影响

外部宏观环境因素在塑造生殖医学市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解性与生殖医学市场的竞争状况

生殖药物市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：性与生殖药物市场供应商的绩效评估

FPNV定位矩阵是评估生殖医学市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製性与生殖医学市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，生殖医学市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 寻求药物的老年妇女人数增加
    • 避孕器的需求，以防止意外怀孕
    • 网路普及率很高，智慧型手机和笔记型电脑也很普及。
  • 抑制因素
    • 治疗和诊断费用高
  • 机会
    • 加强药品研发（R&D）力度
    • 提高妇女对避孕器使用的认识
    • 政府对妇女健康的关注与倡议
  • 任务
    • 与临床服务相关的巨额成本
• 市场区隔分析
• 波特五力分析
• PESTEL分析
  • 政治
  • 经济
  • 社会
  • 科技
  • 法律
  • 环境

第六章 性与生殖医学市场：依药物类型

• 介绍
• 勃起功能障碍治疗
• 性别焦虑药物
• 性慾减退症治疗
• 早洩治疗

第七章 性与生殖医学市场：按分销管道

• 介绍
• 医院药房
• 网路药房
• 零售药房

第八章美洲性与生殖医学市场

• 介绍
• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第九章亚太性与生殖医学市场

• 介绍
• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十章欧洲、中东和非洲的性与生殖医学市场

• 介绍
• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十一章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
• 战略分析和建议

公司名单

• Bayer AG
• Bristol Laboratories Ltd.
• Church & Dwight Co., Inc.
• Diamond Products
• Ferring BV
• Janssen Pharmaceutical Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Reckitt Benckiser Group PLC
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Viramal Limited

The Sexual & Reproductive Health Drugs Market was valued at USD 31.64 billion in 2023, expected to reach USD 35.83 billion in 2024, and is projected to grow at a CAGR of 13.34%, to USD 76.03 billion by 2030.

The market for sexual and reproductive health drugs encompasses a broad array of pharmaceuticals designed to address reproductive health issues and sexual wellness. This scope includes contraceptives, hormonal therapy, menopause management drugs, drugs for erectile dysfunction, and treatments for sexually transmitted infections. The necessity of these drugs stems from the persistent global demand for effective reproductive health solutions, driven by factors such as a growing population, rising awareness of sexual health, and increased acceptance of sexual wellness products. Applications stretch across contraception, fertility treatments, gender affirmation therapy, and management of hormonal disorders, with significant end-use by individuals, healthcare providers, and clinics dedicated to sexual health. Key growth influencers include advancements in biotechnology, increasing healthcare access, and sociocultural shifts toward embracing sexual health as a critical component of overall well-being. Opportunities exist in expanding access through telehealth solutions and developing personalized medicine approaches, with a focus on addressing unmet needs in underrepresented populations. However, challenges persist, such as regulatory hurdles, societal stigma surrounding certain drugs, and potential side effects that hinder widespread adoption. Innovation areas ripe for exploration include non-hormonal contraceptives, long-acting reversible contraceptives (LARCs), and drugs targeting specific hormonal pathways with fewer side effects. Additionally, research into new delivery mechanisms, such as nanotechnology, and exploring plant-based or naturally-derived formulations can offer competitive advantages. The nature of the market is highly dynamic and competitive, with continual investment in R&D required to address the evolving needs and preferences of consumers. Companies seeking growth should focus on strategic partnerships, community engagement to reduce stigma, and advocacy for more equitable regulatory frameworks to broaden market reach. Emphasizing education and holistic health approaches will also play a pivotal role in market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sexual & Reproductive Health Drugs Market

The Sexual & Reproductive Health Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising population of the elder female demanding medicines
  • Demand for contraceptives to prevent unintended pregnancies
  • High internet penetration and availability of smartphones and laptops
• Market Restraints
  • High cost of treatment and diagnostics
• Market Opportunities
  • Increasing efforts into research and development (R&D) of drugs
  • Growing awareness among ladies about the use of contraceptives
  • Government concerns and initiatives towards women's health
• Market Challenges
  • Enormous financial costs associated with the clinical services

Porter's Five Forces: A Strategic Tool for Navigating the Sexual & Reproductive Health Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sexual & Reproductive Health Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sexual & Reproductive Health Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sexual & Reproductive Health Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sexual & Reproductive Health Drugs Market

A detailed market share analysis in the Sexual & Reproductive Health Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sexual & Reproductive Health Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sexual & Reproductive Health Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sexual & Reproductive Health Drugs Market

A strategic analysis of the Sexual & Reproductive Health Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sexual & Reproductive Health Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Bristol Laboratories Ltd., Church & Dwight Co., Inc., Diamond Products, Ferring B.V., Janssen Pharmaceutical Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Viramal Limited.

Market Segmentation & Coverage

This research report categorizes the Sexual & Reproductive Health Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drugs Type, market is studied across Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, and Premature Ejaculation Drugs.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising population of the elder female demanding medicines
    • 5.1.1.2. Demand for contraceptives to prevent unintended pregnancies
    • 5.1.1.3. High internet penetration and availability of smartphones and laptops
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment and diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing efforts into research and development (R&D) of drugs
    • 5.1.3.2. Growing awareness among ladies about the use of contraceptives
    • 5.1.3.3. Government concerns and initiatives towards women's health
  • 5.1.4. Challenges
    • 5.1.4.1. Enormous financial costs associated with the clinical services
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Sexual & Reproductive Health Drugs Market, by Drugs Type

• 6.1. Introduction
• 6.2. Erectile Dysfunction Drugs
• 6.3. Gender Dysphoria Drugs
• 6.4. Hypoactive Sexual Desire Disorder Drugs
• 6.5. Premature Ejaculation Drugs

7. Sexual & Reproductive Health Drugs Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Pharmacy
• 7.4. Retail Pharmacy

8. Americas Sexual & Reproductive Health Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Sexual & Reproductive Health Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Sexual & Reproductive Health Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer AG
• 2. Bristol Laboratories Ltd.
• 3. Church & Dwight Co., Inc.
• 4. Diamond Products
• 5. Ferring B.V.
• 6. Janssen Pharmaceutical Inc.
• 7. Merck & Co., Inc.
• 8. Novartis AG
• 9. Pfizer Inc.
• 10. Reckitt Benckiser Group PLC
• 11. Teva Pharmaceutical Industries Ltd.
• 12. Viatris Inc.
• 13. Viramal Limited

LIST OF FIGURES

• FIGURE 1. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GENDER DYSPHORIA DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HYPOACTIVE SEXUAL DESIRE DISORDER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PREMATURE EJACULATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. CANADA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 24. CANADA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CHINA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 38. INDIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ITALY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. POLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 81. POLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. QATAR SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 83. QATAR SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 103. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2023